OCGN · XBRL financial data

Ocugen financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (OCGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	43	0	—	—	—	—
Revenue from contracts with customers	—	—	2,488	6,036	4,055	4,413
Research and development	—	—	—	39,573	32,126	39,750
General and administrative	7,974	22,920	35,111	31,994	26,686	27,579
Total operating expenses	21,327	58,028	84,868	71,567	58,812	67,329
Operating income (loss)	(21,285)	(58,028)	(84,868)	(65,531)	(54,757)	(62,916)
Interest income	1	—	—	—	1,251	922
Interest expense	721	79	—	—	688	5,188
Other income (expense)	183	(310)	—	—	140	(664)
Income tax expense (benefit)	0	(52)	0	0	0	0
Net income (loss)	(21,822)	(58,365)	(81,351)	(63,078)	(54,054)	(67,846)
Earnings per share, basic USD per share	(0.31)	(0.30)	(0.38)	(0.26)	—	—
Earnings per share, diluted USD per share	(0.31)	(0.30)	(0.38)	(0.26)	—	—
Weighted average shares, basic thousands of shares	112,236	195,013	214,600	244,327	—	—
Weighted average shares, diluted thousands of shares	112,236	195,013	214,600	244,327	—	—

Fiscal years (OCGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	24,039	94,958	77,563	39,462	58,821	18,571
Marketable securities	—	0	13,371	0	—	0
Prepaid and other current assets	1,838	2,700	7,558	3,509	3,168	5,769
Total current assets	25,878	102,646	98,492	42,971	61,682	24,340
Property and equipment, net	633	1,164	6,053	17,290	16,554	14,392
Right-of-use asset	434	1,587	3,910	3,944	3,613	4,092
Total assets	27,376	105,761	108,632	64,547	82,442	43,516
Accounts payable	395	2,312	8,062	3,172	4,243	6,202
Accrued liabilities	2,930	4,325	9,900	—	—	—
Current portion of long-term debt	—	—	0	0	1,326	1,250
Total current liabilities	3,614	7,000	18,460	17,089	21,588	23,043
Long-term debt	1,823	1,712	2,289	2,800	27,345	27,542
Lease liability, non-current	389	1,231	3,587	3,567	3,313	3,494
Total liabilities	5,826	9,943	24,580	23,983	52,810	55,682
Accumulated deficit	(73,302)	(131,667)	(213,018)	(286,167)	(340,221)	(408,067)
Total stockholders' equity	21,550	95,818	84,052	40,564	29,632	(12,166)
Total liabilities and equity	27,376	105,761	108,632	64,547	82,442	43,516
Common shares outstanding (cover page) thousands of shares	188,089	199,488	226,418	257,325	292,014	327,897

Fiscal years (OCGN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(21,822)	(58,365)	(81,351)	(63,078)	(54,054)	(67,846)
Depreciation and amortization	—	229	480	—	—	—
Net cash from operating activities	(14,709)	(47,941)	(60,079)	(62,054)	(42,142)	(56,964)
Purchases of property and equipment	307	939	4,457	10,476	3,385	185
Net cash from investing activities	(307)	(1,816)	(16,967)	3,077	(3,385)	(311)
Proceeds from issuing common stock	37,822	129,211	59,567	20,804	38,556	19,854
Share repurchases	0	0	—	—	—	—
Proceeds from long-term debt	—	0	500	—	—	—
Net cash from financing activities	31,611	120,676	59,475	20,881	64,858	17,328
Net change in cash	16,595	70,919	(17,546)	(38,101)	19,359	(39,934)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Ocugen	24,632	1,951	(15,739)*	339.3M	5.1 quarters	Q3 FY26 10-QSep 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Siga Technologies	117,584	41,002	15,174*	71.8M	—	Q2 FY26 10-QJun 30, 2026
Verastem	136,353	40,078	(43,909)*	90.6M	3.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.